ATE541047T1 - Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen - Google Patents
Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinenInfo
- Publication number
- ATE541047T1 ATE541047T1 AT03816723T AT03816723T ATE541047T1 AT E541047 T1 ATE541047 T1 AT E541047T1 AT 03816723 T AT03816723 T AT 03816723T AT 03816723 T AT03816723 T AT 03816723T AT E541047 T1 ATE541047 T1 AT E541047T1
- Authority
- AT
- Austria
- Prior art keywords
- monoclonal antibodies
- therapeutic monoclonal
- botulinum neurotoxins
- antibodies
- neutralizing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40072102P | 2002-08-01 | 2002-08-01 | |
PCT/US2003/024371 WO2005016232A2 (en) | 2002-08-01 | 2003-08-01 | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE541047T1 true ATE541047T1 (de) | 2012-01-15 |
Family
ID=34192937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03816723T ATE541047T1 (de) | 2002-08-01 | 2003-08-01 | Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP2436774A3 (de) |
AT (1) | ATE541047T1 (de) |
AU (1) | AU2003304411A1 (de) |
CA (1) | CA2492883C (de) |
WO (1) | WO2005016232A2 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
WO2007094754A2 (en) | 2005-01-27 | 2007-08-23 | The Regents Of The University Of Califordnia | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
EP2134749B1 (de) | 2007-03-22 | 2013-11-06 | The Regents of the University of California | Therapeutische monoklonale antikörper zur neutralisierung von botulinneurotoxinen |
JP5432727B2 (ja) | 2008-01-29 | 2014-03-05 | 株式会社抗体研究所 | A型ボツリヌス毒素中和組成物及びヒト抗a型ボツリヌス毒素抗体 |
CN102325792B (zh) | 2009-02-19 | 2018-01-09 | 莫茨制药有限及两合公司 | 用于生产高纯度神经毒素的手段和方法 |
NL2002868C2 (en) * | 2009-05-11 | 2010-11-15 | Ibis Technologies B V | Method for the determination of competing interactants binding to a compound, use, combination and apparatus. |
US8821879B2 (en) | 2009-09-04 | 2014-09-02 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
CN104870468B (zh) * | 2012-11-21 | 2020-11-10 | 益普生生物创新有限公司 | 用于制备经蛋白水解处理的多肽的方法 |
CN112870234B (zh) * | 2021-01-27 | 2023-06-02 | 四川九章生物科技有限公司 | 包含绿原酸的药物组合物在制备治疗病理性黄疸的药物中的用途 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4254082A (en) | 1978-06-12 | 1981-03-03 | Miles Laboratories, Inc. | Specific binding-adsorbent assay test means |
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
JPS58215453A (ja) | 1982-06-09 | 1983-12-14 | Toray Silicone Co Ltd | 室温硬化後塗装可能なオルガノポリシロキサン組成物 |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5001065A (en) | 1987-05-27 | 1991-03-19 | Cetus Corporation | Human cell line and triomas, antibodies, and transformants derived therefrom |
JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5231026A (en) | 1987-12-31 | 1993-07-27 | Tanox Biosystems, Inc. | DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
US5292867A (en) | 1988-11-16 | 1994-03-08 | Tanox Biosystems, Inc. | Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin |
IL94872A (en) | 1989-06-30 | 1995-03-30 | Oncogen | Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the |
US5075431A (en) | 1989-07-26 | 1991-12-24 | City Of Hope | Chimeric anti-CEA antibody |
US5081235A (en) | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
US5472693A (en) | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
US5506132A (en) | 1993-07-28 | 1996-04-09 | Sandoz Pharmaceuticals Corporation | Human antibodies against varicella-zoster virus |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
US5691447A (en) | 1995-03-24 | 1997-11-25 | Tanox Biosystems, Inc. | GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies |
US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US20020155114A1 (en) * | 1998-08-31 | 2002-10-24 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US6667158B1 (en) * | 1998-12-17 | 2003-12-23 | The United States Of America As Represented By The Secretary Of The Army | Antibodies against type a botulinum neurotoxin |
WO2005030119A2 (en) * | 2003-04-11 | 2005-04-07 | Allergan, Inc. | Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
TWI552751B (zh) | 2011-06-20 | 2016-10-11 | H 朗德貝克公司 | 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌及其鹽用於治療精神分裂症的方法 |
-
2003
- 2003-08-01 AU AU2003304411A patent/AU2003304411A1/en not_active Abandoned
- 2003-08-01 EP EP11190090A patent/EP2436774A3/de not_active Withdrawn
- 2003-08-01 CA CA2492883A patent/CA2492883C/en not_active Expired - Lifetime
- 2003-08-01 AT AT03816723T patent/ATE541047T1/de active
- 2003-08-01 WO PCT/US2003/024371 patent/WO2005016232A2/en not_active Application Discontinuation
- 2003-08-01 EP EP03816723A patent/EP1572121B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2005016232A3 (en) | 2005-09-15 |
AU2003304411A8 (en) | 2005-03-07 |
WO2005016232A2 (en) | 2005-02-24 |
AU2003304411A1 (en) | 2005-03-07 |
CA2492883C (en) | 2012-10-02 |
EP1572121A2 (de) | 2005-09-14 |
EP1572121B1 (de) | 2012-01-11 |
EP2436774A3 (de) | 2012-06-13 |
CA2492883A1 (en) | 2005-02-01 |
EP1572121A4 (de) | 2007-11-07 |
EP2436774A2 (de) | 2012-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007094754A3 (en) | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins | |
WO2009008916A3 (en) | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins | |
LTPA2017022I1 (lt) | Antikūnai prieš Clostridium difficile toksinus ir jų panaudojimas | |
WO2010014854A3 (en) | Antibodies that neutralize botulinum neurotoxins | |
DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
DK1534335T3 (da) | FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf | |
DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
ATE520416T1 (de) | Menschliche anti-ifn-gamma-neutralisierende antikörper als selektive inhibitoren des ifn- gamma-wegs | |
EE200700052A (et) | Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu | |
SI1639011T1 (sl) | Pegilirana protitelesa z enojno domeno (dAb) | |
DE60005953D1 (de) | Stapelbare statische mischelemente | |
ATE549358T1 (de) | Neuer anti-plgf-antikörper | |
EA200701452A1 (ru) | Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4) | |
ATE545657T1 (de) | Tgf-beta antikörper | |
EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
DK1706424T3 (da) | FC-region varianter | |
DK1734995T3 (da) | Monoklonale antistoffer og hepatocyytvækstfaktor | |
ATE541047T1 (de) | Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen | |
ATE485517T1 (de) | Verfahren zur identifizierung von polypeptid- targets | |
BR0315042A (pt) | Terapia para o tratamento de aterosclerose baseada em imunização passiva por peptìdeo | |
DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
GB0324656D0 (en) | A protein involved in ovarian cancer | |
GB0312642D0 (en) | Pharmaceutical composition | |
ATE492564T1 (de) | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum | |
DE602006009257D1 (de) | Verwendung von urokinase-inhibitoren zur behandlunklerose (als) |